All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Nivolumab Offers Long-Term DFS Benefits in Urothelial Carcinoma

May 14th 2022

According to longer follow-up data from the phase 3 CheckMate 274 trial, patients with high-risk, muscle-invasive urothelial carcinoma continued to experience clinically meaningful improvements in disease-free survival when treated with adjuvant nivolumab vs placebo.

18F-rhPSMA-7.3 Increases Upstaging of Disease in Recurrent Prostate Cancer

May 13th 2022

PET/CT scans conducted with 18F-rhPSMA-7.3 frequently resulted in post-scan disease upstaging compared with baseline conventional imaging in patients with prostate cancer recurrence.

N-803 Plus BCG Produces Clinically Meaningful Benefit in BCG-Unresponsive Bladder Cancer

May 13th 2022

The addition of the IL15RaFc superagonist N-803 to Bacillus Calmette–Guérin led to prolonged complete responses and disease-free survival (DFS) in patients with BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ and papillary histology, respectively.

Immune-Related Adverse Effects Linked to Longer Survival With Pembrolizumab in Metastatic Urothelial Carcinoma

May 13th 2022

Patients with metastatic urothelial carcinoma who received pembrolizumab achieved prolonged median progression-free and overall survival after experiencing an immune-related adverse effect.

Stanford Faculty Break Down Advancements in Women’s Cancer Care

May 13th 2022

Advancements in treatment options across the spectrum on women’s cancers include de-escalating therapy in HER2-positive breast cancer, using tisotumab vedotin-tftv in cervical cancer, shifting therapies to the frontline setting in endometrial cancer, and using checkpoint inhibitors in ovarian cancer.

Sotigalimab Plus Nivolumab Shows Encouraging Activity in Anti–PD-1 Refractory Melanoma

May 13th 2022

The combination of sotigalimab and nivolumab elicited durable responses with a reasonable safety profile in patients with melanoma who were refractory to anti–PD-1 therapy, according to data from a phase 2 trial.

Precision Medicine Advances in Cancer Treatment Highlighted at Inaugural Sylvester Conference

May 13th 2022

Innovative advances in personalized care, immunotherapy, and targeted treatment for people with many types of cancer were the focus of the inaugural Miami Precision Medicine Conference, held April 2 at the Ritz-Carlton in Fort Lauderdale.

Navicixizumab/Paclitaxel Combo Demonstrates Early Promise in Platinum-Resistant Ovarian Cancer

May 13th 2022

The addition of navicixizumab to paclitaxel produced encouraging responses with manageable toxicity in patients with platinum-resistant ovarian cancer irrespective of prior treatment with bevacizumab.

Emerging Targeted Therapies Continue to Shift Paradigm in EGFR Exon 20–Mutated NSCLC

May 12th 2022

Edward Kim, MD, MBA, discussed the facets of each presentation from the meeting, featuring other emerging targeted therapies in NSCLC, biomarker testing in the space, frontline immunotherapy in NSCLC, and the current management of small cell lung cancer.

Pilot Study Shows Promising Results With CPX-351 in Relapsed/Refractory ALL

May 12th 2022

Bijal Shah, MD, MS, discusses the results of a phase 2 pilot study investigating CPX-351 in adults with high-risk relapsed/refractory acute lymphoblastic leukemia, as well as next steps for research in this patient population.

Sexual Harassment Rates Across Oncology Call for Improved Policies and Protections

May 12th 2022

Seventy percent of practicing oncologists had experienced sexual harassment by peers or superiors within 1 year, highlighting a substantial issue for both women and men, according to findings from a study that were published in the Journal of Clinical Oncology.

Ovarian Suppression with GnRH Agonists Can Aid Fertility Preservation in Breast Cancer

May 12th 2022

Treatment regimens that include ovarian suppression with a gonadotropin-releasing hormone agonist have gained momentum in recent years as a potential solution to address treatment-related early menopause for women with breast cancer.

$3.5 Million NIH Grant to Rutgers Cancer Institute of New Jersey Will Support a New ‘Lens’ in Lung Cancer Screening

May 12th 2022

With the aid of a $3.5 million National Institutes of Health grant, investigators from Rutgers Cancer Institute of New Jersey, along with Holden Cancer Center at the University of Iowa, and the University of Texas MD Anderson Cancer Center, are collaborating on a project to address lung cancer screening disparities among individuals with a history of heavy smoking

New Treatment Options Are in Play for Relapsed/ Refractory DLBCL

May 12th 2022

Up to 40% of patients with diffuse large B-cell lymphoma are refractory to or relapse after first-line treatment.

Targeted Therapies Continue to Expand the Treatment Paradigm in NSCLC

May 12th 2022

The treatment landscape continues to expand across non–small cell lung cancer, with the FDA approvals of multiple agents, including targeted therapies such as sotorasib and lorlatinib.

Vibostolimab/Pembrolizumab Combo Elicits Antitumor Activity in Metastatic Cervical Cancer

May 11th 2022

Two investigated doses of vibostolimab in combination with pembrolizumab resulted in comparable antitumor activity and safety in patients with locally advanced or metastatic cervical cancer who were naïve to PD-1/PD-L1 inhibitors, regardless of PD-L1 status.

FDA Grants Breakthrough Designation to Repotrectinib for Pretreated, ROS1+ Metastatic NSCLC

May 11th 2022

The FDA has granted a breakthrough therapy designation to repotrectinib for the treatment of patients with ROS1-positive metastatic non–small cell lung cancer who have been previously treated with one ROS1 TKI and have not received prior platinum-based chemotherapy.

Cabozantinib Plus Nivolumab Shows Efficacy in Papillary Non–Clear Cell RCC

May 11th 2022

The combination of cabozantinib plus nivolumab demonstrated promising objective response rates in patients with non–clear cell renal cell carcinoma with prominent papillary features.

Frontline Tiragolumab/Atezolizumab Combo Misses PFS End Point in PD-L1–High Metastatic NSCLC

May 11th 2022

The anti-TIGIT immunotherapy tiragolumab in combination with atezolizumab did not improve progression-free survival over atezolizumab alone in the first-line treatment of patients with PD-L1–high locally advanced or metastatic non–small cell lung cancer.

Entrectinib Continues to Yield Promising Data in NTRK Fusion–Positive Breast Cancer

May 11th 2022

Entrectinib produced deep and durable responses in patients with breast cancer harboring NTRK fusions.